ClinicalTrials.gg
Status unknownNCT03664388CardioCHUVIUpdated Sep 10, 2018

Registry of Acute Coronary Syndrome From University Hospital of Vigo

An observational study in Acute Coronary Syndrome, sponsored by Hospital Álvaro Cunqueiro. Status unknown at 1 site in Spain. Per ClinicalTrials.gov, last updated 2018-09-10.

Sponsored by Hospital Álvaro Cunqueiro · Observational

How we know

The sponsor has not verified this record recently (last verified Sep 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
8,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Acute Coronary Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Acute Coronary Syndrome · Spain.

Planned enrollment
3rd of 25
8,000 · median 900
Started
2016
with 4 others
Observational
25 of 85
3 open now
Registered
50th of 85
by date

Among the 85 studies in Acute Coronary Syndrome with a site in Spain, this one is the 3rd largest by planned enrollment of the 25 observational ones that give a count, is one of 5 that started in 2016, is one of 25 observational ones, and was the 50th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

13 of the 85 studies in Acute Coronary Syndrome with a site in Spain are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Acute Coronary Syndrome with a site in Spain, or all of them as a file.
02

Study summary

CardoCHUVI registry was aim to study ischemic and bleeding complication after an acute coronary syndrome (ACS), both in-hospital and follow-up events.

Read the detailed description

CardioCHUVI is a retrospective study aim to analyze all consecutively patients admitted by acute coronary syndrome to University Hospital Alvaro Cunqueiro of Vigo, between January 2010 to January 2018

The objective of the project was to study cardiac and bleeding complications, such as reinfarction, heart failure, atrial fibrillation, stroke, and bleeding events, together with all-cause and cardiac mortality

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • Acute Coronary Syndrome; Bleeding; Dual antiplatelet therapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients admitted by acute coronary syndrome in the University Hospital Alvaro Cunqueiro of Vigo between January 2010 to January 2018

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient admitted to University Hospital Alvaro Cunqueiro of Vigo for acute coronary syndrome.

Exclusion criteria

Exclusion Criteria:

  • Secondary acute coronary syndromes during a hospital admission for another cause (i.e. acute myocardial infarction in the context of a sepsis)
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
8,000 participants (estimated)
Patient registry
No

Interventions

  • DrugDual antiplatelet therapy with ticagrelor/prasuglre

    Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy

    Also known as: Dual antiplatelet therapy with clopidogrel

06

What researchers measure

Primary outcomes

  1. All cause mortality

    Death for any cause

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. Reinfarction

    New spontaneous acute myocardial infarction

    Time frame: Through study completion, an average of 3 years

  2. Bleeding

    Any bleeding according to BARC definition (from 1 to 5)

    Time frame: Through study completion, an average of 3 years

  3. Ischemic stroke

    Ischemic stroke documented in CT

    Time frame: Through study completion, an average of 3 years

  4. Cancer

    Any type of malignant cancer

    Time frame: Through study completion, an average of 3 years

  5. Heart Failure

    Heart Failure admissions

    Time frame: Through study completion, an average of 3 years

  6. Atrial Fibrillation

    Atrial fibrillation documented in ECG

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiology, Hospital Álvaro Cunqueiro
    Vigo, Pontevedra 36312, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Registry of all consecutive patients admitted by acute coronary syndrome (ACS) to an university hospital in order to analyze bleeding and ischemic complications according to the type and duration of dual antiplatelet therapy

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Sep 2018, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2018
First posted
Sep 10, 2018
StartActual
Feb 1, 2016
Primary completionActual
Sep 6, 2018
CompletionEst.
Feb 1, 2020
Last update
Sep 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03664388
Lead sponsor
Hospital Álvaro Cunqueiro
Responsible party
Sponsor
First posted
Sep 10, 2018
Start date
Feb 1, 2016
Primary completion
Sep 6, 2018
Completion
Feb 1, 2020 (estimated)
Last update
Sep 10, 2018

Study contacts

Sergio Raposeiras Roubín, MD, PhD
Contact
raposeiras26@hotmail.com
0034 620170387
Emad Abu Assi, MD, PhD
Contact
eabuassi@gmail.com
Emad Abu-Assi, MD, PhD
study chair · University Hospital Álvaro Cunqueiro, Vigo, Spain
Sergio Raposeiras-Roubín, MD, PhD
principal investigator · University Hospital Álvaro Cunqueiro, Vigo, Spain
Andres Iñiguez-Romo, MD, PhD
study director · University Hospital Álvaro Cunqueiro, Vigo, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion